Bonds Morgan, Rocha Flavio G
Section of General, Thoracic and Vascular Surgery, Virginia Mason Medical Center, Seattle, WA 98101, USA.
J Clin Med. 2019 Aug 12;8(8):1205. doi: 10.3390/jcm8081205.
Borderline resectable pancreatic adenocarcinoma (PDAC) presents challenges in definition and treatment. Many different definitions exist for this disease. Some are based on anatomy alone, while others include factors such as disease biology and patient performance status. Regardless of definition, evidence suggests that borderline resectable PDAC is a systemic disease at the time of diagnosis. There is high-level evidence to support the use of neoadjuvant systemic therapy in these cases. Evidence to support the use of radiation therapy is ongoing. There are ongoing trials investigating the available neoadjuvant therapies for borderline resectable PDAC that may provide clarity in the future.
可切除边缘性胰腺癌（PDAC）在定义和治疗方面存在挑战。针对这种疾病存在许多不同的定义。有些仅基于解剖学，而其他定义则包括疾病生物学和患者体能状态等因素。无论定义如何，有证据表明可切除边缘性PDAC在诊断时即为全身性疾病。有高级别证据支持在这些病例中使用新辅助全身治疗。支持使用放射治疗的证据仍在不断涌现。目前正在进行试验，研究针对可切除边缘性PDAC的可用新辅助治疗方法，这些研究可能在未来提供明确的结果。
